Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology

Stock Information for Ensysce Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ensysce Biosciences Inc.

Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
Ensysce Biosciences Expands Global Opioid Patent Portfolio
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
Ensysce Biosciences Issues Annual Shareholder Letter

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.